Inter-individual variability in esterases in human liver

Biochemical Pharmacology

Volumn 74, Issue 6, 2007, Pages 932-939

  Jewell, Christopher ^a   Bennett, Phillippa ^a   Mutch, Elaine ^a   Ackermann, Chrisita ^b   Williams, Faith M ^a  

^a School of Clinical   (United Kingdom)

^b PFIZER INC   (United States)

Author keywords

Carboxylesterase; Human; Liver; Metabolism; Parabens

Indexed keywords

4 HYDROXYBENZOIC ACID ESTER; ALCOHOL; BENZYL PARABEN; BUTYL PARABEN; CARBOXYLESTERASE; ETHYL PARABEN; HYDROXYBENZOIC ACID; PROPYL PARABEN; UNCLASSIFIED DRUG; VALERIC ACID DERIVATIVE; VALERIC ACID PHENYL ESTER;

ARTICLE; CHEMICAL STRUCTURE; CONTROLLED STUDY; CYTOSOL; ENZYME ACTIVITY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN TISSUE; HYDROLYSIS; INDIVIDUALIZATION; LIVER METABOLISM; LIVER MICROSOME; PRIORITY JOURNAL; PROTEIN DETERMINATION; REACTION TIME; STATISTICAL ANALYSIS;

CYTOSOL; ESTERASES; ESTERS; HUMANS; HYDROLYSIS; KINETICS; LIVER; MICROSOMES, LIVER; REPRODUCIBILITY OF RESULTS;

EID: 34547655648     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bcp.2007.06.022     Document Type: Article

References (35)

1. Zhang W., Xu G., and McLeod H.L. Comprehensive evaluation of carboxylesterase-2 expression in normal human tissues using tissue array analysis. Appl Immunohistochem Mol Morphol 10 (2002) 374-380
2. Redinbo M.R., and Potter P.M. Mammalian carboxylesterases: from drug targets to protein therapeutics. Drug Discov Today 10 (2005) 313-325
3. Graffner-Nordberg M., Sjodin K., Tunek A., and Hallberg A. Synthesis and enzymatic hydrolysis of esters, constituting simple models of soft drugs. Chem Pharm Bull (Tokyo) 46 (1998) 591-601
4. Buchwald M., and Bodor N. Quantitative structure-metabolism relationship: steric and nonsteric effects in the enzymatic hydrolysis of noncongener carboxylic esters. J Med Chem 42 (1999) 5160-5168
5. Xie M., Yang D., Liu L., Xue B., and Yan B. Human and rodent carboxylesterases: immunorelatedness, overlapping substrate specificity, differential sensitivity to serine enzyme inhibitors and tumor-related expression. Drug Metab Dispos 30 (2002) 541-547
6. Williams F.M. Clinical significance of esterases in man. Clin Pharmacokinet 10 (1985) 392-403
7. Huang T.L., Dhiotsuki T., Uematsu T., Borhan B., Li Q.X., and Hammock B.D. Structure activity relationships for substrates and inhibitors of mammalian liver microsomal carboxylesterases. Pharm Res 13 (1996) 1495-1500
8. Satoh T., and Hosokawa M. The mammalian carboxylesterases: from molecules to functions. Annu Rev Pharmacol Toxicol 38 (1998) 257-288
9. Shibata F., Takagi Y., Kitajima M., Kuroda T., and Omura T. Molecular cloning and characterisation of a human carboxylesterase gene. Genomics 17 (1993) 76-82
10. Pindel E.V., Kedishvili N.Y., Abraham T.L., Brzezinski M.R., Zhang J., Dean R.A., et al. Purification and cloning of a broad substrate specificity human liver carboxylesterase that catalyses the hydrolysis of cocaine and heroin. J Biol Chem 272 (1997) 14769-14775
11. Sanghani S.P., Quinney S.K., Fredenburg T.B., Sun Z., Davis W.I., Murry D.J., et al. Hydrolysis of irinotecan and its oxidative metabolites, 7-ethyl-10-[4-N-(5-aminopentanoic acid)-1-piperidino] carbonyloxycamptothecin and 7-ethyl-10-[4-1-piperdino)-1-amino]-carbonyloxycamptothecin, by human carboxylesterases CES1A1, CES2, and a newly expressed carboxylesterase isoenzyme, CES3. Drug Metab Dispos 32 (2004) 505-511
12. Zhang J., Burnell J.C., Dumaual N., and Bosron W.F. Binding and hydrolysis of meperidine by human liver carboxylesterase hCE-1. J Pharmacol Exp Ther 290 (1999) 314-318
13. Sun Z., Murry D.J., Sanghani S.P., Davis W.I., Kedishvili N.Y., Zou Q., et al. Methylphenidate is stereoselectively hydrolysed by human carboxylesterase CES1A1. J Pharmacol Exp Ther 310 (2004) 469-476
14. Bosron W.F., and Hurley T.D. Lessons from a bacterial cocaine esterase. Nat Struct Mol Biol 9 (2002) 4-5
15. Takai S., Matsuda A., Usami Y., Adachi T., Sugiyama T., Katagiri Y., et al. Hydrolytic profile for ester- or amide- linkage by carboxylesterases pI5.3 and 4. 5 for human liver. Biol Pharm Bull 20 (1997) 869-873
16. Lobemeier C., Tschoetschel C., Westie S., and Heymann E. Hydrolysis of parabenes by extracts from differing layers of human skin. Biol Chem 377 (1996) 647-651
17. Golden R., Gandy J., and Vollmer G. A review of the endocrine activity of parabens and implications for potential risks to human health. Crit Rev Toxicol 35 (2005) 435-458
18. Harvey P.W., and Everett D.J. Editorial: Significance of the detection of esters of p-hydroxybenzoic acid (parabens) in human breast tumours. J Appl Toxicol 24 (2004) 1-4
19. Nakagawa Y., and Moldeus P. Mechanism of p-hydroxybenzoate ester induced mitochondrial dysfunction and cytotoxicity in isolated rat hepatocytes. Biochem pharmacol 55 (1998) 1907-1914
20. Handa O., Kokura S., Adachi S., Takagi T., Naito Y., Tanigawa T., et al. Methyparaben potentiates UV-induced damage of skin keratinocytes. Toxicology 227 (2006) 62-72
21. Geshi E., Kimura T., Yosyimura M., Suziki H., Koba S., Sakai T., et al. A single nucleotide polymorphism in the carboxylesterase gene is associated with the responsiveness to imidapril medication and the promotor activity. Hepertens Res 28 (2006) 719-725
22. Marsh S., Xiao M., Yu J., Ahluwalia R., Minton M., Freimuth R.R., et al. Pharmacogenomic assessment of carboxylesterases 1 and 2. Genomics 84 (2004) 661-668
23. Wu M.H., Chen P., Wu X., Liu W., Strom S., Das S., et al. Determination and anlysis of single nucleotide polymorphisms and haplotype structure of the human carboxylesterase 2 gene. Pharmacogenetics 14 (2004) 595-605
24. Tabata T., Katoh M., Tokudome S., Nakajima M., and Yokoi T. Identification of the cytolsolic carboxylesterase catalyzing the 5′-deoxy-5-fluorocytidine formation from capecitabine in human liver. Drug Metab Dispos 32 10 (2004) 1103-1110
25. Quinney S.K., Sanghani S.P., Davis W.P., Hurley T.D., Sun Z., Murry D.J., et al. Hydrolysis of capecitabine to 5′-deoxy-5-fluorocytidine by human carboxylesterases and inhibition by loperamide. J Pharmacol Exp Ther 313 (2005) 1011-1016
26. Mutch E., and Williams F.M. Do multiple cytochrome P450 isoforms contribute to parathion metabolism in man?. Arch Toxicol 77 (2003) 313-320
27. Mutch E., and Williams F.M. Diazinon, chlorpyrifos and parathion are metabolised by multiple cytochromes P450 in human liver. Toxicology 224 (2006) 22-32
28. Mutch E. The role of metabolism in determining susceptibility to parathion toxicity. PhD thesis, Newcastle University, U.K. 1998.
29. Smith P.K., Krohn R.I., Hermanson G.T., Mallia A.K., Gartner F.H., Provenzano M.D., et al. Measurement of protein using bicinchoninic acid. Anal Biochem 150 (1985) 76-85
30. Jewell C., Ackerman C., Payne N.A., Fate G., Voorman R., and Williams F.M. Specificity of procaine hydrolysis by human, minipig and rat skin and liver. Drug Metab Dispos (2007) Submitted
31. Brzezinski M.R., Abraham T.R., Stone C.L., Dean R.A., and Bosron W.F. Purification and characterisation of a human liver cocaine carboxylesterase that catalyses the production of benzoylecgonine and the formation of cocaethylene from alcohol and cocaine. Biochem Pharmacol 48 (1994) 1747-1755
32. Imai T., Tekatani M., Shii M., Hosokawa M., and Chiba K. Substrate specificity of carboxylesterase isozymes and their contribution to hydrolase activity in human liver and small intestine. Drug Metab Dispos 34 (2006) 1734-1741
33. Ross M.K., Borazjani A., Edwards C.C., and Potter P.M. Hydrolytic metabolism of pyrethroids by human and other mammalian carboxylesterases. Biochem Pharmacol 71 (2006) 657-669
34. Imai T. Human carboxylesterase isozymes: catalytic properties and rational drug design. Drug Metab Pharmacokinet 21 (2006) 173-185
35. Crow J.A., Borazjani A., Potter P.M., and Ross M.K. Hydrolysis of pyrethroids by human and rat tissues: examination of intestinal, liver and serum carboxylesterases. Toxicol Appl Parmacol 221 (2007) 1-12